Hepatitis

This poster states three important facts people should know about hepatitis C: it's a leading cause of liver cancer, millions of Americans have it, but don't know it, and treatments can eliminate the virus. The poster advises individuals to talk to their doctor about getting tested. The poster is also available in a smaller size, 26" x 36", at http://www.cdc.gov/knowmorehepatitis/media/pdfs/poster-facts24x36.pdf.

This poster states three important facts people should know about hepatitis C: it's a leading cause of liver cancer, millions of Americans have it, but don't know it, and treatments can eliminate the virus. The poster advises individuals to talk to their doctor about getting tested. The poster is also available in a smaller size, 8.5" x 11", at http://www.cdc.gov/knowmorehepatitis/Media/PDFs/Poster-Facts.pdf.

This poster targets African American men informing them that Hepatitis C virus (HCV) infection can lead to liver cancer. It also emphasizes the importance of getting tested for HCV and that early detection can save lives.

This poster targets African American men informing them that Hepatitis C virus (HCV) infection can lead to liver cancer. It also emphasizes the importance of getting tested for HCV and that early detection can save lives.

This poster emphasizes the need to get tested for hepatitis C. It states that most people have no symptoms for hepatitis C but still may have the disease, which leads to liver cancer. A 24" x 36" poster can be ordered at: http://wwwn.cdc.gov/pubs/CDCInfoOnDemand.aspx?Pubid=221237.

This poster encourages Americans born between 1945 and 1965 to get tested for hepatitis C virus (HCV) because they are at high risk of having the disease.

This online course teaches the user how to evaluate abnormal liver chemistries in the context of a broad understanding of the pathophysiology of liver injury. It is designed for providers who are non-liver specialists, particularly mid-level healthcare providers. Participants will learn common differential diagnosis for each pattern of liver injury, to initiate appropriate investigations based on the pattern of liver injury, recognize clinical manifestations of hepatic failure, and identify patients with liver disease who require hospitalization.

This internet file (web page) provides lessons on co-infection of HIV and hepatitis C. It discusses treatment; responder relapsers, partial responders, and null responders; experimental treatment; preventing cellular infection; viral enzyme target; immune therapies; and prevention. It includes two video clips, one with a hepatitis C patient, who relates her story, and the other with a doctor explains the importance of knowing about HCV for HIV infected individuals.

This guide details safety, efficacy, and access information on rifapentine. The guide also provides activists with the evidence and content needed to advocate for rifapentine to be available, accessible, and affordable to those who may need it.

This workbook is designed for patient's use throughout treatment with triple therapy--pegylated interferon, ribavirin, and boceprevir. The workbook explains triple therapy, how and when to take medications, what to do if you miss a dose, the length of treatment, if treament does not work, treatment tracks and which you should follow, and dealing with side effects. It provides sample medication schedules, a viral load chart, the notes to bring to the provider, and treatment visit schedule.